Hemostemix Stock Price, News & Analysis

Hemostemix (OTCQB: HMTXF) has successfully completed a non-brokered private placement, raising $2,969,600 through the sale of 29,696,000 units at $0.10 per unit. Each unit comprises one common share and one warrant exercisable at $0.15 for two years.

The company will use the proceeds to repay CD#1 at a 50% discount to face value ($1,250,000) and for general working capital, including marketing and sales of VesCell™. The placement included participation from directors Peter Lacey and Loran Swanberg. Additionally, Hemostemix granted 3,870,000 stock options to directors, officers, employees, and consultants at $0.13 per share, expiring July 23, 2030.

Hemostemix (OTCQB: HMTXF) has announced the closing of a sale of 15 ACP-01 Therapy Convertible Debentures (TCD) for USD $517,230, pending TSXV Exchange approval. The TCDs are convertible into ACP-01 therapy treatments or common shares at $0.155 per share, featuring a 6% annual interest rate payable in shares and a maturity date of December 31, 2029.

As an autologous stem cell therapy company, Hemostemix has successfully treated 498 patients for various cardiovascular diseases. The company's ACP-01 therapy has demonstrated clinical significance in treating conditions including peripheral arterial disease, chronic limb threatening ischemia, and various forms of heart disease. The new TCD structure enables the company to sell therapy blocks to clinics, investors, and high-net-worth individuals without diluting shareholder equity.

[ "Introduction of innovative TCD financing structure that allows forward sale of treatments without equity dilution", "Successfully treated 498 patients and completed 7 clinical studies with 318 subjects", "Demonstrated clinical significance in multiple cardiovascular conditions", "6% annual interest rate on TCDs provides additional value to investors" ]

Hemostemix (OTCQB: HMTXF) has expanded its previously announced private placement from $2.5 million to $3 million due to oversubscription. The company is offering Units at $0.10 each, consisting of one Common Share and one Warrant exercisable at $0.15 for two years.

Notable insider participation includes Chairman Peter Lacey ($1.5 million) and Director Loran Swanberg ($100,000). The proceeds will be used to repay CD#1 at a 50% discount to face value ($1.25 million) and for general working capital to support operational expenses, including marketing and sales of VesCell™.

Hemostemix (OTCQB: HMTXF) has announced an oversubscribed private placement, raising $2.7 million through a non-brokered offering, exceeding the initial target of $2.5 million. The company is issuing units at $0.10, with each unit comprising one common share and one warrant exercisable at $0.15 for two years.

Chairman Peter Lacey led the placement with a $1.5 million subscription. Additionally, the company has negotiated a debt settlement of $400,000 at $0.20 per share. Proceeds will be used to repay CD#1 and support working capital, including marketing and sales of VesCell™.

Hemostemix (OTCQB: HMTXF) has successfully closed a non-brokered private placement offering, raising CAD $469,366 through the issuance of 3,911,385 Common Shares at CAD $0.12 per share. The TSX Venture Exchange has granted conditional approval for this offering.

The funds will be directed towards general working capital, operational expenses, and business development activities. The issued securities are subject to a four-month hold period under Canadian securities laws. The investor is confirmed to be arm's length to the company and not a Related Party.

Hemostemix (OTCQB: HMTXF) has published its 10th scientific paper detailing ACP-01's molecular strategy for treating heart failure, specifically focusing on non-ischemic dilated cardiomyopathy (DCM). The publication highlights how ACP-01's unique characteristics differentiate it from traditional bone marrow-derived cell therapies.

The company's previous studies demonstrated that cardiac function improved by up to 47.1% after one ACP-01 treatment in DCM patients. ACP-01's effectiveness is attributed to three key mechanisms: precise migration to injured tissue through CXCR4 expression, attraction of Natural Killer cells to reduce inflammation and fibrosis, and improved microcirculation through angiogenesis.

Following Florida's new law permitting non-FDA approved stem cell treatments, Hemostemix is now offering ACP-01 therapy to no-option DCM patients in Florida.

Hemostemix (OTCQB:HMTXF) announced the appointment of Croom Lawrence as Chief Commercialization Officer. The company has partnered with Lawrence to offer MCI Screen, an FDA-approved and insurer-reimbursed advanced cognitive test for Vascular Dementia. The company noted that their ACP-01 treatment has shown clinical success in reversing vascular dementia in one patient for over ten years.

Hemostemix (OTCQB: HMTXF) announced a significant financial restructuring, with Chairman Peter Lacey providing a $1.5 million lead order for a non-brokered private placement at $0.10 per Unit. Each Unit includes one Common Share and one Warrant exercisable at $0.15 for two years. $1.25 million will be used to fully repay a $2.5 million Convertible Debenture.

The placement is part of a larger offering totaling up to $2.5 million. The company also confirmed the conversion price of previously announced ACP-01 Therapy Convertible Debentures (TCD) at CAD $0.155, relating to the March 5 sale of 15 TCDs for $708,605.

Hemostemix (HMTXF) has closed a non-brokered private placement raising CAD $469,366 through the issuance of 3,911,385 common shares at CAD $0.12 per share, pending TSXV Exchange approval. The securities will have a four-month hold period from closing. The proceeds will support general working capital, operational expenses, and business development. Hemostemix is an autologous stem cell therapy company that has developed ACP-01, a blood-based stem cell therapy. The company has completed seven clinical studies with 318 subjects, with results published in nine peer-reviewed publications. Their Phase II clinical trial for chronic limb threatening ischemia showed promising results, including 0% mortality and 83% wound healing in patients followed for up to 4.5 years.